GACT 5113 Managerial Accounting Final Assessment 2026 | Unirazak

GACT 5113 Final Assessment

Instructions To Candidates

1. Please answer ALL questions.
2. Type your answers in Times New Roman Font 12 with 1.5 Spacing 3. Submit the answer’s soft copy through the course’s UROX platform.
3. The similarity index should be less than 20%.
4. You are required to submit the final assessment on time. Any reason for the late submission will not be entertained.

Case Study Questions (100 Marks)

Attempt ALL questions.

Question 1 (25 Marks)

Zenith Electronics is a premier manufacturer of high-end home theater systems. For the past five years, they have dominated the luxury market with their flagship “Aura” sound system. However, the market is shifting toward mid-range, integrated smart-home audio solutions. Zenith’s management is now at a crossroads: they must decide whether to continue investing in the low-volume, high-margin luxury segment or pivot to a high-volume, lower-margin mass-market product called “Sonic.” The “Aura” system currently sells for 12,000 per unit with a variable cost of 7,000, while the proposed “Sonic” would sell for 4,000 with a variable cost of 2,800. Zenith’s total fixed costs, including specialized factory leases and executive salaries, remain a significant burden at 15 million per annum. The marketing department argues that the “Sonic” will allow Zenith to capture a 30% market share in the smart-home sector, but the production team is concerned that the existing manufacturing facility lacks the automation required for such high-volume output.

The CFO, Michael Chen, is tasked with performing a CVP analysis to determine the break-even point for both products. He is particularly concerned about the “Margin of Safety,” as the global economy is showing signs of a slowdown, which typically hits luxury goods harder than mid-range electronics. Additionally, Michael must consider the “Operating Leverage” of the firm. Zenith has recently invested heavily in robotic assembly lines to reduce labour costs, which has effectively traded variable costs for higher fixed depreciation costs. This shift means that while Zenith can be more profitable at high volumes, its “Degree of Operating Leverage” is now much higher, making the company more vulnerable if sales targets are not met. The board of directors is also pressuring Michael to calculate a “Target Profit” that would satisfy shareholder expectations for the March 2026 semester.

The complexity increases when considering a “Sales Mix” strategy. Zenith could potentially sell both products simultaneously, but this creates a risk of “product cannibalization,” where loyal customers might choose the cheaper “Sonic” over the premium “Aura.” The management must decide on the optimal ratio of sales between the two products to maximize the weighted-average contribution margin. Furthermore, external factors such as fluctuating raw material prices for semi-conductors add a layer of uncertainty to the variable cost projections. Michael knows that a simple break-even chart is not enough for an MBAlevel decision; he must explain to the board how sensitivity in any of these variables price, variable cost, or fixed cost could drastically alter the company’s risk profile and long-term viability.

Required:

a. Calculate the profit made on each unit (Contribution Margin) for both Aura and Sonic.

(2 Marks)

b. Calculate how many units of Aura Zenith needs to sell to break even, assuming it remains the only product sold.

(3 Marks)

c. Assume Zenith decides to sell both products at the same time. For every 1 Aura sold, they expect to sell 3 Sonic systems (a 1:3 mix).

i. Calculate the average profit earned per mix combo.

(4 Marks)

ii. Calculate how many total units Zenith must sell to achieve a Target Profit of 5 million. How many of these will be Aura and how many will be Sonic?

(4 Marks)

iii. Briefly explain the risk of product cannibalization if customers decide to buy the cheaper Sonic instead of the premium Aura.

(2 Marks)

d. Zenith recently invested heavily in robotic assembly lines. This move increased their Fixed Costs (due to machine depreciation) but lowered their Variable Costs (due to less manual labour), resulting in a high Operating Leverage.

Critically evaluate how this new cost structure affects Zenith’s financial risk.

In your answer, discuss what will happen to the company’s profits if sales skyrocket, what will happen if sales drop due to an economic slowdown, and why the Margin of Safety is now a critical metric for the CFO to monitor.

(10 Marks)

(Total: 25 Marks)

Question 2 (25 Marks)

Precision Engineering (PE) is a specialized firm that provides custom-made components for the aerospace and medical device industries. For over twenty years, PE has used a traditional Job-Order Costing system, where manufacturing overhead is applied to jobs based on a single plant-wide rate using direct labour hours. In the early days, this was effective because labour was the primary driver of production. However, over the last decade, PE has transformed into a high-tech facility. Direct labour now accounts for less than 10% of total production costs, while overhead costs driven by sophisticated CNC machinery, software licenses, quality inspections, and clean-room maintenance—have skyrocketed. The current system is producing alarming results: PE is consistently winning bids for complex, small-batch medical implants but losing bids for large-scale, simpler aerospace brackets to competitors who are significantly cheaper.

The Managing Director, Fatima Zahra, suspects that the company is suffering from “Product Cost Distortion.” Because the traditional system allocates overhead based on labour hours, the simple aerospace brackets, which require significant labour for manual finishing, are being over-costed. Meanwhile, the complex medical implants, which are highly automated but require intense engineering support and setup time, are being under-costed. This means PE might actually be losing money on the very medical contracts they are so proud of winning. Fatima is considering a shift to Activity-Based Costing (ABC) to provide a more accurate picture. She wants to identify specific cost pools such as “Machine Setups,” “Quality Control Inspections,” and “Engineering Design Hours” to see the true consumption of resources by each product line.

The transition to a new costing system is not just a technical challenge but a cultural one. The production managers are resistant to ABC, arguing that the time required to track “cost drivers” like setup hours or number of inspections is a distraction from their primary goal of meeting delivery deadlines. They are also worried that if the “true cost” of the medical implants is revealed to be much higher, the company might lose its most prestigious clients. Fatima must also consider the concept of “Time-Driven Activity-Based Costing” or “Lean Accounting” to simplify the process. She needs to convince the board that the current lack of accurate cost data is leading to poor strategic decisions, incorrect pricing, and a portfolio of products that is financially unsustainable. The challenge is to find a balance between the precision of the data and the cost of maintaining the system itself.

Required:

a. Explain the general trade-off in accounting between data precision (accuracy) and the cost/effort of operating a system.

(4 Marks)

b. Analyse whether Fatima’s dilemma between getting highly accurate data and keeping the process simple for her busy managers reflect this trade-off?

(6 Marks)

c. Critique why employees and managers often resist changing to a new costing system in a company.

(5 Marks)

d. Referencing the case scenario, evaluate any THREE (3) specific reasons why Precision Engineering’s (PE) production managers are against switching to Activity-Based Costing (ABC).

(10 Marks)

(Total: 25 Marks)

Question 3 (25 Marks)

AeroComponent Manufacturing (ACM) produces high-precision parts for the aerospace industry. The company operates in a highly regulated environment where quality and safety are paramount. For the past decade, ACM has used a traditional, rigid “top-down” annual budgeting process. Every October, the executive team sets strict cost-reduction targets for the following year, which are then cascaded down to the floor managers. Bonuses are tied strictly to meeting these budget targets—specifically, achieving favorable labour and material price variances. In the most recent fiscal year, the production department reported record-breaking favourable variances, suggesting that they were operating much more efficiently than planned. On paper, the manufacturing plant appeared to be a model of cost-efficiency.

However, a parallel report from the Quality Assurance (QA) and Customer Relations departments painted a very different picture. The rate of defective parts returned by clients had tripled, and ACM recently narrowly avoided a catastrophic failure in a client’s engine during a ground test. An internal investigation revealed that in order to meet the aggressive favorable material variance targets, the purchasing manager had switched to a lower-grade alloy from a new, unvetted supplier. Furthermore, to achieve favourable labour variance, floor managers had reduced the time spent on mandatory safety inspections and had cut back on the specialized training hours for junior technicians. The “efficiency” shown in the budget was, in reality, a result of managers “gaming the system” to secure their bonuses at the expense of long-term product integrity and brand reputation.

The CEO is now considering a radical overhaul of the budgeting process. Some consultants have suggested “Participative Budgeting,” where floor managers have a say in setting their own targets, hoping this will lead to more realistic and “honest” budgets. Others suggest “Beyond Budgeting,” arguing that in a volatile industry like aerospace, a fixed annual budget is obsolete by the second month of the year and that the company should instead use “Rolling Forecasts” and relative performance contracts. The Finance Director, however, is terrified of losing control. He fears that without strict, fixed top-down targets, costs will spiral out of control and managers will build “Budgetary Slack” (padding their budgets) to make their targets even easier to hit. ACM stands at a crossroad where it must decide if its budgeting system is a tool for coordination or a weapon for coercion.

Required:

a. Analyse how a company’s budget can look “perfect” on paper while its internal operations are failing.

(10 Marks)

b. Based on the parallel reports from ACM (Production vs. Quality Assurance), critically evaluate THREE (3) argument why traditional financial budgets are insufficient on their own for a highly regulated industry like aerospace.

(15 Marks)

(Total: 25 Marks)

Question 4 (25 Marks)

BioPharma Solutions has recently developed LifeFlow, a breakthrough life-saving medication for a rare chronic condition that previously had no effective treatment. The company spent RM200 million over eight years in Research and Development (R&D) to bring LifeFlow to market. As they prepare for the March 2026 launch, the executive committee is debating the optimal pricing strategy. The production cost (variable cost) per dose is remarkably low at only RM50. However, the Finance Director argues for a Value-Based Pricing model, proposing a price of RM5,000 per dose. This high price is justified by the immense value the drug provides to patients potentially adding ten years to their life expectancy and the need to recoup the massive R&D sunk costs and fund future innovation. Under this model, BioPharma would achieve a high contribution margin and provide a rapid Return on Investment (ROI) for its shareholders.

Conversely, the Public Relations and Ethics Committee is advocating for a Cost-Plus Pricing or Social Justice model. They suggest a price of RM250 per dose, which covers the variable cost and a fair share of overheads while ensuring the drug is accessible to low-income patients and government-funded healthcare systems. They warn that a high price point will lead to price gouging accusations, damaging the company’s long-term brand equity and potentially inviting strict government price regulations. The Sales Director adds a third perspective, suggesting a “Market Skimming” strategy: start with a very high price for private insurance holders and gradually lower the price over three years as competitors develop similar synthetic alternatives. This would maximize profits in the short term but risks alienating the patient community who need the drug immediately.

The decision is further complicated by the global supply chain. If BioPharma prices the drug too low in one region, “Parallel Importing” might occur, where third-party distributors buy the drug in low-price markets and resell it in high-price markets, eroding the company’s controlled revenue streams. The board must also consider the “Opportunity Cost” of the manufacturing capacity; the facility used for LifeFlow could instead produce high-volume over-the-counter medications with stable, predictable returns. As an MBA-level decision, the final price cannot be determined by a simple formula; it must balance the fiduciary duty to shareholders, the ethical obligation to patients, and the strategic need to protect the company from future regulatory and competitive threats in a volatile global healthcare market.

Required:

a. Discuss why sunk costs not affect future decisions?

(2 Marks)

b. Explain why the RM200 million spent on R&D should technically be ignored when making future pricing decisions.

(3 Marks)

c. Evaluate why it is practically very difficult for BioPharma’s management to ignore this massive investment when launching LifeFlow.

(5 Marks)

d. Assume BioPharma expects to sell 50,000 doses of LifeFlow globally in its first year, and the company’s fixed overhead allocation for this product line is RM10 million for the year.

i. If BioPharma adopts the Cost-Plus Pricing model (RM250 per dose) as suggested by the Ethics Committee, calculate the total revenue and the total profit (or loss) the company would make in the first year.

(5 Marks)

ii. If BioPharma adopts the Value-Based Pricing model (RM5,000 per dose) as suggested by the Finance Director, calculate the total revenue and the total profit the company would make in the first year.

(5 Marks)

 iii. Calculate how many doses BioPharma must sell to completely recoup (break even on) their RM200 million R&D investment under both pricing models.

(5 Marks)

(Total: 25 Marks)

[TOTAL: 100 MARKS]

End Of Question Paper